vs
Side-by-side financial comparison of Cognizant (CTSH) and Fresenius Medical Care AG (FMS). Click either name above to swap in a different company.
Fresenius Medical Care AG is the larger business by last-quarter revenue ($5.5B vs $5.4B, roughly 1.0× Cognizant). Cognizant runs the higher net margin — 12.2% vs 7.9%, a 4.3% gap on every dollar of revenue. On growth, Cognizant posted the faster year-over-year revenue change (5.8% vs -0.3%).
Cognizant Technology Solutions Corporation is an American multinational information technology consulting and outsourcing company originally founded in India. It is headquartered in Teaneck, New Jersey, United States. Cognizant is part of the NASDAQ-100 and trades under CTSH. It was founded in Chennai, India, as an in-house technology unit of Dun & Bradstreet in 1994, and started serving external clients in 1996.
Fresenius Medical Care AG & Co. KGaA is a German healthcare company which provides kidney dialysis services through a network of 4,171 outpatient dialysis centers, serving 345,425 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo dialysis 3 times per week for the rest of their lives.
CTSH vs FMS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.4B | $5.5B |
| Net Profit | $662.0M | $434.2M |
| Gross Margin | — | 27.4% |
| Operating Margin | 15.6% | 11.7% |
| Net Margin | 12.2% | 7.9% |
| Revenue YoY | 5.8% | -0.3% |
| Net Profit YoY | -0.2% | 240.4% |
| EPS (diluted) | $1.39 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $5.4B | — | ||
| Q4 25 | $5.3B | $5.5B | ||
| Q3 25 | $5.4B | — | ||
| Q2 25 | $5.2B | — | ||
| Q1 25 | $5.1B | — | ||
| Q4 24 | $5.1B | $5.5B | ||
| Q3 24 | $5.0B | — | ||
| Q2 24 | $4.8B | — |
| Q1 26 | $662.0M | — | ||
| Q4 25 | $648.0M | $434.2M | ||
| Q3 25 | $274.0M | — | ||
| Q2 25 | $645.0M | — | ||
| Q1 25 | $663.0M | — | ||
| Q4 24 | $546.0M | $127.6M | ||
| Q3 24 | $582.0M | — | ||
| Q2 24 | $566.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 27.4% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 25.0% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | 15.6% | — | ||
| Q4 25 | 16.0% | 11.7% | ||
| Q3 25 | 16.0% | — | ||
| Q2 25 | 15.6% | — | ||
| Q1 25 | 16.7% | — | ||
| Q4 24 | 14.8% | 5.1% | ||
| Q3 24 | 14.6% | — | ||
| Q2 24 | 14.6% | — |
| Q1 26 | 12.2% | — | ||
| Q4 25 | 12.2% | 7.9% | ||
| Q3 25 | 5.1% | — | ||
| Q2 25 | 12.3% | — | ||
| Q1 25 | 13.0% | — | ||
| Q4 24 | 10.7% | 2.3% | ||
| Q3 24 | 11.5% | — | ||
| Q2 24 | 11.7% | — |
| Q1 26 | $1.39 | — | ||
| Q4 25 | $1.35 | — | ||
| Q3 25 | $0.56 | — | ||
| Q2 25 | $1.31 | — | ||
| Q1 25 | $1.34 | — | ||
| Q4 24 | $1.10 | — | ||
| Q3 24 | $1.17 | — | ||
| Q2 24 | $1.14 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.5B | $1.7B |
| Total DebtLower is stronger | $568.0M | — |
| Stockholders' EquityBook value | $15.1B | $15.4B |
| Total Assets | $20.5B | $33.5B |
| Debt / EquityLower = less leverage | 0.04× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.9B | $1.7B | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $1.8B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.2B | $1.3B | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $2.2B | — |
| Q1 26 | $568.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $15.1B | — | ||
| Q4 25 | $15.0B | $15.4B | ||
| Q3 25 | $14.9B | — | ||
| Q2 25 | $15.3B | — | ||
| Q1 25 | $14.9B | — | ||
| Q4 24 | $14.4B | $17.0B | ||
| Q3 24 | $14.5B | — | ||
| Q2 24 | $13.9B | — |
| Q1 26 | $20.5B | — | ||
| Q4 25 | $20.7B | $33.5B | ||
| Q3 25 | $20.1B | — | ||
| Q2 25 | $20.2B | — | ||
| Q1 25 | $20.0B | — | ||
| Q4 24 | $20.0B | $36.3B | ||
| Q3 24 | $20.2B | — | ||
| Q2 24 | $18.6B | — |
| Q1 26 | 0.04× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $274.0M | $2.9B |
| Free Cash FlowOCF − Capex | $198.0M | — |
| FCF MarginFCF / Revenue | 3.7% | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 0.41× | 6.67× |
| TTM Free Cash FlowTrailing 4 quarters | $2.5B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $274.0M | — | ||
| Q4 25 | $858.0M | $2.9B | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $398.0M | — | ||
| Q1 25 | $400.0M | — | ||
| Q4 24 | $920.0M | $2.6B | ||
| Q3 24 | $847.0M | — | ||
| Q2 24 | $262.0M | — |
| Q1 26 | $198.0M | — | ||
| Q4 25 | $781.0M | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $331.0M | — | ||
| Q1 25 | $323.0M | — | ||
| Q4 24 | $837.0M | — | ||
| Q3 24 | $791.0M | — | ||
| Q2 24 | $183.0M | — |
| Q1 26 | 3.7% | — | ||
| Q4 25 | 14.6% | — | ||
| Q3 25 | 21.4% | — | ||
| Q2 25 | 6.3% | — | ||
| Q1 25 | 6.3% | — | ||
| Q4 24 | 16.5% | — | ||
| Q3 24 | 15.7% | — | ||
| Q2 24 | 3.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.1% | — | ||
| Q2 24 | 1.6% | — |
| Q1 26 | 0.41× | — | ||
| Q4 25 | 1.32× | 6.67× | ||
| Q3 25 | 4.48× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | 0.60× | — | ||
| Q4 24 | 1.68× | 20.20× | ||
| Q3 24 | 1.46× | — | ||
| Q2 24 | 0.46× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
